The 36-month beta value for EWTX is also noteworthy at 0.19. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for EWTX is 67.23M, and at present, short sellers hold a 12.99% of that float. The average trading volume of EWTX on March 13, 2025 was 1.06M shares.
EWTX) stock’s latest price update
Edgewise Therapeutics Inc (NASDAQ: EWTX)’s stock price has plunge by -8.07relation to previous closing price of 27.40. Nevertheless, the company has seen a -5.69% plunge in its stock price over the last five trading sessions. businesswire.com reported 2025-03-11 that BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The conference will take place at the Hilton Anatole, Dallas, TX from March.
EWTX’s Market Performance
EWTX’s stock has fallen by -5.69% in the past week, with a monthly drop of -4.37% and a quarterly drop of -22.71%. The volatility ratio for the week is 9.85% while the volatility levels for the last 30 days are 7.51% for Edgewise Therapeutics Inc The simple moving average for the last 20 days is -4.12% for EWTX stock, with a simple moving average of 0.65% for the last 200 days.
Analysts’ Opinion of EWTX
Many brokerage firms have already submitted their reports for EWTX stocks, with Scotiabank repeating the rating for EWTX by listing it as a “Sector Outperform.” The predicted price for EWTX in the upcoming period, according to Scotiabank is $50 based on the research report published on March 07, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see EWTX reach a price target of $30. The rating they have provided for EWTX stocks is “Hold” according to the report published on January 22nd, 2025.
Evercore ISI gave a rating of “Outperform” to EWTX, setting the target price at $45 in the report published on November 22nd of the previous year.
EWTX Trading at -6.25% from the 50-Day Moving Average
After a stumble in the market that brought EWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.92% of loss for the given period.
Volatility was left at 7.51%, however, over the last 30 days, the volatility rate increased by 9.85%, as shares sank -3.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.07% lower at present.
During the last 5 trading sessions, EWTX fell by -5.69%, which changed the moving average for the period of 200-days by +38.56% in comparison to the 20-day moving average, which settled at $26.27. In addition, Edgewise Therapeutics Inc saw -5.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EWTX starting from Russell Alan J, who sale 200 shares at the price of $30.02 back on Mar 07 ’25. After this action, Russell Alan J now owns 14,863 shares of Edgewise Therapeutics Inc, valued at $6,004 using the latest closing price.
KOCH KEVIN, the President and CEO of Edgewise Therapeutics Inc, sale 100 shares at $30.00 during a trade that took place back on Mar 07 ’25, which means that KOCH KEVIN is holding 14,478 shares at $3,000 based on the most recent closing price.
Stock Fundamentals for EWTX
The total capital return value is set at -0.34. Equity return is now at value -34.40, with -32.37 for asset returns.
Based on Edgewise Therapeutics Inc (EWTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -23.02.
Currently, EBITDA for the company is -158.83 million with net debt to EBITDA at 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.93.
Conclusion
In summary, Edgewise Therapeutics Inc (EWTX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
